- Home
- IONS vs NEU Comparison
IONS vs NEU Comparison
Compare IONS & NEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- NEU
- Stock Information
- Founded
- IONS 1989
- NEU 1887
- Country
- IONS United States
- NEU United States
- Employees
- IONS N/A
- NEU N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- NEU Major Chemicals
- Sector
- IONS Health Care
- NEU Industrials
- Exchange
- IONS Nasdaq
- NEU Nasdaq
- Market Cap
- IONS 6.8B
- NEU 7.9B
- IPO Year
- IONS 1991
- NEU N/A
- Fundamental
- Price
- IONS $69.15
- NEU $861.95
- Analyst Decision
- IONS Strong Buy
- NEU
- Analyst Count
- IONS 18
- NEU 0
- Target Price
- IONS $72.83
- NEU N/A
- AVG Volume (30 Days)
- IONS 2.2M
- NEU 89.6K
- Earning Date
- IONS 11-05-2025
- NEU 10-30-2025
- Dividend Yield
- IONS N/A
- NEU 1.30%
- EPS Growth
- IONS N/A
- NEU 17.77
- EPS
- IONS N/A
- NEU 50.47
- Revenue
- IONS $944,050,000.00
- NEU $2,779,049,000.00
- Revenue This Year
- IONS $24.01
- NEU N/A
- Revenue Next Year
- IONS $4.06
- NEU N/A
- P/E Ratio
- IONS N/A
- NEU $16.76
- Revenue Growth
- IONS 16.05
- NEU 2.27
- 52 Week Low
- IONS $23.95
- NEU $480.00
- 52 Week High
- IONS $69.25
- NEU $854.75
- Technical
- Relative Strength Index (RSI)
- IONS 80.12
- NEU 66.73
- Support Level
- IONS $61.03
- NEU $826.65
- Resistance Level
- IONS $63.18
- NEU $851.15
- Average True Range (ATR)
- IONS 1.63
- NEU 14.70
- MACD
- IONS 0.02
- NEU 0.54
- Stochastic Oscillator
- IONS 89.41
- NEU 91.52
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About NEU NewMarket Corp
NewMarket Corp is a holding company that, through its subsidiaries, manufactures and sells petroleum additives. Petroleum additives are used in lubricating oils and fuels to enhance their performance in machinery, vehicles, and other equipment. It comprises two broad product applications. Lubricant additives are formulated chemical solutions that, when blended with base fluids, improve the efficiency, durability, performance, and functionality of mineral oils, synthetic oils, and biodegradable fluids. Fuel additives are chemical components that help oil refiners meet fuel specifications or formulated packages that improve the performance of gasoline, diesel, biofuels, and other fuels.